ArriVent BioPharma, Inc. AVBP EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by ArriVent BioPharma, Inc. in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The official record: ArriVent BioPharma, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about ArriVent BioPharma, Inc.'s eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ArriVent BioPharma, Inc.'s EPS (diluted)?
- ArriVent BioPharma, Inc. (AVBP) reported EPS (diluted) of -$0.96 in Q1 2026.
- How has ArriVent BioPharma, Inc.'s EPS (diluted) changed year-over-year?
- ArriVent BioPharma, Inc.'s EPS (diluted) increased by 49.5% year-over-year, from -$1.90 to -$0.96.
- What is the long-term trend for ArriVent BioPharma, Inc.'s EPS (diluted)?
- Over 2 years (2023 to 2025), ArriVent BioPharma, Inc.'s EPS (diluted) has grown at a -63.7% compound annual growth rate (CAGR), from -$33.45 to -$4.41.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.